An adaptive pharmacological approach for the individualisation of voriconazole antifungal therapy

ISRCTN ISRCTN83902726
DOI https://doi.org/10.1186/ISRCTN83902726
EudraCT/CTIS number 2013-002578-34
ClinicalTrials.gov number NCT01887457
Secondary identifying numbers UoL001025
Submission date
14/07/2014
Registration date
24/10/2014
Last edited
12/06/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Progressive (invasive) fungal infections are a major cause of many diseases and even death in patients with tumors affecting the blood and in those needing a treatment called haematopoietic stem cell transplantation. Invasive fungal infections often prevent the affected patient being able to have chemotherapy or transplantation. New ways to give an ideal antifungal therapy are urgently required. A drug called Voriconazole can be used for the prevention of invasive fungal infections. Research suggests that voriconazole exhibits clinically relevant drug exposure-response and drug-exposure toxicity relationships. Invasive fungal infections are deadly; therefore it is important to monitor the drug intake to ensure individual patient’s drug exposures are ideal. But there are no computer programs that can tell us how much drug should be given and at what intervals that enable the correct dosage in a timely and optimally precise manner. A computer program for this purpose has been developed. The software is used to individualise voriconazole regimens in patients to ensure they achieve desired levels and are deemed by that clinician to be safe and effective. The aim of this study is to find out how safe and effective this computer software is.

Who can participate?
Patients requiring treatment for invasive fungal infections..

What does the study involve?
Patients are required to stay in hospital and receive treatment every 12 hours for 5 days. In addition, patients have 13 blood samples taken during treatment. As part of the standard treatment patients are required to return to hospital on day 14, and day 35. During these visits patients have a medical examination, a blood sample taken, provide details of any other medications they are taking and on day 35 they may have a CT scan.

What are the possible benefits and risks of participating?
It is hoped that the treatments will help patients. However, this cannot be guaranteed. The information from this study may help to improve the future treatment of patients with invasive fungal infections. Voriconazole is generally well tolerated. The most common side effects experienced with voriconazole are liver disturbances, visual disturbances, skin rash, neurological disturbances, cardiovascular events, blood disorders, kidney disturbances, fever, vomiting, nausea, diarrhoea, headache, peripheral oedema, abdominal pain. Patients are required to have extra blood tests as part of the study. These may cause some bruising and soreness however this should be minor.

Where is the study run from?
Royal Liverpool University Hospital (UK)

When is the study starting and how long is it expected to run for?
August 2014 to August 2016

Who is funding the study?
National Institute for Health Research (NIHR) (UK)

Who is the main contact?
Prof. William Hope
hopew@liverpool.ac.uk

Contact information

Prof William Hope
Scientific

Antimicrobial Pharmacodynamics and Therapeutics
Department of Molecular and Clinical Pharmacology
University of Liverpool
1.09 Sherrington Building
Liverpool
L69 3GE
United Kingdom

Study information

Study designPhase II registered single-centre medical device study
Primary study designInterventional
Secondary study designNon randomised study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleAn adaptive Pharmacological approach for the Individualisation of VOriconazole AntifungaL therapy (PIVOTAL): a Phase II registered single-centre medical device study
Study acronymPIVOTAL
Study objectivesIncreasing evidence suggests that voriconazole exhibits clinically relevant drug exposure-response and drug-exposure toxicity relationships. Trough concentrations < 1 mg/L are associated with a higher probability of clinical failure, while trough concentrations > 5.5-6 mg/L are associated with a higher probability of toxicity. Invasive fungal infections are rapidly lethal; therefore, there are strong grounds to offer therapeutic drug monitoring to ensure individual patient’s drug exposures are optimal.
Ethics approval(s)NRES Committee North West – Liverpool Central, 09/12/2014, ref: 14/NW/1323
Health condition(s) or problem(s) studiedInvasive fungal infection
InterventionVoriconazole is administered over 5 days. Treatment will be given every 12 hours, each treatment will be given over 2 hours via an intravenous drip, so there will be ten 2-hour treatments in total. After consenting initially through part 1 of the consent patients will receive three of these treatments, which are the same as standard treatment.

In addition, five blood samples will be taken, one 10 ml sample before the second treatment and then 5 ml samples taken 1, 3, 6 and 12 hours after the second infusion. Half of the first sample will be stored for future research, the other samples will be used to identify the best dose.

In addition, 5 ml blood samples will be taken before the fifth and tenth treatments, and further 5 ml blood samples taken at 1, 3, 6 and 12 hours after the fifth and tenth treatments. The samples taken before and after the fifth dose will be used to identify the best dose. The samples taken before and after the tenth dose will be used to assess whether the dose given was effective.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase II
Drug / device / biological / vaccine name(s)Voriconazole
Primary outcome measureThe safety and efficacy of computer software to attain pre-defined plasma concentrations of voriconazole for immunocompromised patients. Successful therapy is a trough concentration of 1-3 mg/L at the end of the 10th dosing interval on day 10.
Secondary outcome measures1. Toxicity of patients receiving individualised voriconazole dosing at 35 days
2. Mortality of patients receiving individualised voriconazole dosing at 35 days
Overall study start date01/08/2014
Completion date31/08/2017

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants33
Total final enrolment19
Key inclusion criteria1. Patients ≥18 years old
2. Patients where a new course of voriconazole is indicated for prevention or treatment of an invasive fungal infection
3. Patients with sufficient venous access to enable repeated blood samples
4. Estimated creatinine clearance ≥ 50 mL/min
5. Able to give written informed consent
6. Able to remain in the hospital for at least 5 days
7. Willing to use adequate contraception if necessary
Key exclusion criteria1. Estimated creatinine clearance < 50 mL/minute
2. Use of haemodialysis or haemofiltration
3. Hepatic insufficiency (Child’s B or C)
4. Hepatitis with LFTs > three-times upper limit of normal
5. Pregnancy, breastfeeding or planning pregnancy during the study
6. Past history of intolerance to voriconazole
7. Microbiological evidence of resistance to voriconazole
8. QT prolongation (see 20.6 page 68)
9. Use of other medications that contraindicate the use of voriconazole
10. Hypersensitivity to voriconazole, its excipients or other triazole antifungal agents
Date of first enrolment01/08/2014
Date of final enrolment01/08/2016

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

University of Liverpool
Liverpool
L69 3GE
United Kingdom

Sponsor information

University of Liverpool (UK)
University/education

Cancer Research UK Liverpool Cancer Trials Unit
University of Liverpool
Block C Waterhouse Building
1-3 Brownlow Street
Liverpool
L69 3GL
England
United Kingdom

Website https://www.lctu.org.uk
ROR logo "ROR" https://ror.org/04xs57h96

Funders

Funder type

Government

National Institute for Health Research (NIHR) (UK)
Government organisation / National government
Alternative name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 27/03/2019 12/06/2019 Yes No
HRA research summary 28/06/2023 No No

Editorial Notes

12/06/2019: Publication reference and total final enrolment added.
04/08/2017: The overall trial end date was changed from 01/08/2016 to 31/08/2017.
01/04/2016: Ethics approval information added.